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Abstract
The conversion of 5-aminoimidazole ribonucleotide (AIR) to 4-carboxy-AIR
(CAIR) represents an unusual divergence in purine biosynthesis: microbes
and nonmetazoan eukaryotes use class I PurEs while animals use class II
PurEs. Class I PurEs are therefore a potential antimicrobial target; how-
ever, no enzyme activity assay is suitable for high throughput screening
(HTS). Here we report a simple chemical quench that fixes the PurE sub-
strate/product ratio for 24 h, as assessed by the Bratton-Marshall assay
(BMA) for diazotizable amines. The ZnSO4 stopping reagent is proposed to
chelate CAIR, enabling delayed analysis of this acid-labile product by BMA
or other HTS methods.
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De novo purine biosynthesis harbors an unusual divergence in a ubiq-1
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uitous biosynthetic pathway [1]. In most microbes and nonmetazoan eu-2
karyotes, a class I PurE [PurE1, N 5-carboxyaminoimidazole ribonucleotide3
(NCAIR) mutase, EC 5.4.99.18] reversibly converts NCAIR to 4-carboxy-5-4
aminoimidazole ribonucleotide (CAIR) (Fig. 1) [2]. Animals produce CAIR5
by a different route, using a class II PurE (PurE2, 5-aminoimidazole ribonu-6
cleotide (AIR) carboxylase, EC 4.1.1.21) [3, 4, 5]. Microbial pathogenesis7
relies upon purine biosynthesis [6], particularly purE1, which is therefore a8
promising but unexploited antibiotic target [7, 8]. Inhibitors selective for9
PurE1 could have antibacterial, antifungal, or herbicidal activity [9]. In this10
work, we describe a functional assay for PurE that is compatible with in-11
hibitor identification by high-throughput screening (HTS) methods.12
Currently available PurE functional assays are not amenable to HTS13
methods. A continuous ultraviolet (UV) assay that monitors the absorbance14
decrease due to CAIR decarboxylation [10, 11, 2] is subject to spectral in-15
terference by many candidate inhibitors. CAIR synthesis assays are compli-16
cated by the acid lability of the NCAIR substrate [12, 13, 2], the need for17
multiple coupling enzymes [14, 9], and, for discontinuous assays detecting in-18
organic phosphate production, handling of malachite green reagent [15] and19
a background due to formation of phosphate by the coupling enzymes. The20
Bratton-Marshall assay (BMA) [16] was used in early studies of PurE2 [3],21
but seldom thereafter. The BMA yields intensely colored AIR and CAIR22
derivatives, AIR-BM and CAIR-BM (Fig. 1), that possess characteristic vis-23
ible absorbance spectra [17], are relatively stable, and might be suitable for24
HTS methods. The BMA, however, requires multiple timed reagent additions25
that would be difficult to implement during parallel screens. An alternative26
2
would be to stop the PurE reaction prior to BMA workup using a reagent27
that does not alter product yields.28
The first task was to determine an extinction coefficient for CAIR-BM at29
500 nm, a goal that requires pure CAIR. A new CAIR synthesis, which uses30
LiOH to saponify aminoimidazole-4-carboxamide ribonucleotide (AICAR)31
[18] and thereby facilitates salt removal (see Experimental Procedures in the32
Supplementary material), furnished CAIR in high yield (85%) and purity33
(99%). No signal corresponding to AIR H2 was observed in 1H NMR spectra34
(Fig. S1 in the Supplementary material). Mass spectrometry (MS) analy-35
sis of BMA reaction mixtures revealed only the expected molecular ions for36
single BM adducts and ions present in control mixtures (Table S1 in the Sup-37
plementary material). HPLC analysis of CAIR subjected to BMA workup38
showed 97% CAIR-BM / 3% AIR-BM (Fig. S2 in the Supplementary mate-39
rial); a small amount of AIR evidently forms during the BMA acid quench40
step. CAIR-BM appears to consist of a mixture of species that cannot be41
resolved by HPLC but that possess the same molecular formula. An isobaric42
mixture might also account for the complex shape of the CAIR-BM visible43
spectrum (Fig. S3 in the Supplementary material). Aliquots of a solution44
containing pure CAIR were (1) used to determine an accurate CAIR concen-45
tration, by complete enzymatic conversion to AIR followed by BMA analysis,46
and (2) used to obtain a spectrum of CAIR-BM, which gave εCAIR-BM500 = 11 20047
M−1 cm−1 (for comparison, εAIR-BM500 = 24 800 M
−1 cm−1[17]).48
The second task was to identify an enzyme quenching method that is49
compatible with BMA workup and product analysis. CAIR and analogues50
form stable complexes in which aminoimidazole N3 and O7 atoms (Fig. 1)51
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coordinate a transition metal ion [19]. (CAIR)n-metal (n = 2 or 3) complexes52
(Fig. S4 in the Supplementary material) do not bind to or inhibit chicken53
PurE2 in the presence of excess free CAIR [20, 21, 22]. Mg2+ inhibits PurE2-54
mediated CAIR decarboxylation but not AIR carboxylation, consistent with55
the formation of a low-affinity metal-CAIR complex [10, 4]. To determine if56
transition metals can rapidly and reversibly form CAIR-metal complexes, a57
ten-fold molar excess (relative to the initial CAIR concentration) of NiSO4 or58
ZnSO4 was added to UV-monitored CAIR decarboxylation reaction mixtures.59
CAIR decarboxylation stopped immediately, but could be restarted by the60
addition of EDTA (Fig. S5 in the Supplementary material). EDTA had no61
effect on BMA workup; the initial acidification step apparently dissociates62
CAIR complexes formed with either Ni2+ or Zn2+.63
Zn2+ appeared to form a CAIR complex with higher kinetic stability than64
Ni2+, and to pose fewer concerns with regard to toxicity, spectral overlap65
with (C)AIR-BM, and redox chemistry. A CAIR decarboxylation reaction66
mixture incubated at 30 ◦C was stopped at ∼30% completion by the addition67
of ∼3 molar equivalents of ZnSO4 (Fig. 2). Equivalent yields of CAIR-BM68
were obtained if the BMA workup was delayed by up to 4 h. In contrast,69
Ni2+-stopped reactions lost CAIR at the rate of about 10% per h at 3070
◦C (data not shown). A saturation curve employing ZnSO4 quenching gave71
kinetic constants similar to the standard continuous UV assay (Fig. S6 in72
the Supplementary material). Indistinguishable velocities were obtained at73
40 µM CAIR for a quenched reaction worked up promptly or after a 24 h74
delay. Therefore ZnSO4 is a suitable stopping reagent for PurE reaction75
mixtures.76
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Metal stopping reagents are proposed to work by rapid substrate de-77
pletion, an uncommon mode of enzyme inhibition (e.g., vancomycin [24])78
[25]. Immobilized metal affinity chromatography (IMAC) was used to test if79
CAIR binds to Ni2+, immobilized on a nitrilotriacetic acid (NTA) column.80
An equimolar mixture of CAIR and AIR was applied to the NiNTA column.81
The first column fraction contained pure AIR, consistent with selective re-82
tention of CAIR on the column as a CAIR-Ni2+ complex (Figs. S7 and S8 in83
the Supplementary material). Subsequent fractions contained CAIR, indicat-84
ing that the Ni2+-CAIR interaction was reversible (data not shown). While85
these results do not exclude the possibility that PurE is inhibited by direct86
protein-metal interactions, they indicate that the rapid formation of a stable87
CAIR-transition metal complex is sufficient to account for ZnSO4-mediated88
arrest of CAIR decarboxylation.89
In summary, we have identified a PurE reaction quencher that facilitates90
HTS using the BMA as a detection method. PurE-mediated CAIR decar-91
boxylation stopped by a single liquid addition, of a ZnSO4 solution, allows92
delayed BMA workup. The BMA is compatible with candidate inhibitors93
that absorb UV light, a common practical concern for detecting initial hits,94
which often have low potency and therefore require high compound concen-95
trations that cause significant spectral interference. BMA-detected PurE96
screens require no other enzymes and can be used to screen candidate in-97
hibitors that do not contain diazotizable amines or strong metal chelators.98
The metal stopping reagent could be adapted for use with other detection99
methods or in assays of 5-aminoimidazole-4-N -succinylcarboxamide ribonu-100
cleotide (SAICAR) synthetase (PurC, EC 6.3.2.6), the other enzyme known101
5
to use CAIR as a substrate. SAICAR has recently been shown to activate102
cancer metabolism via pyruvate kinase isoform M2 [26].103
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Figure Captions214
Figure 1: PurE1 reaction and CAIR/AIR detection by Bratton-Marshall215
assay (BMA). NCAIR decarboxylates to AIR (half-life of 0.9 min at pH 7.8216
and 30 ◦C) during the enzyme assay [2], an acid-dependent process that goes217
to completion during the BMA. R5P = ribosyl 5′-phosphate, R = H (AIR-218
BM) or COO− (CAIR-BM). CAIR aminoimidazole atoms are numbered as219
in PDB residue type C2R. CAIR atoms proposed to coordinate transition220
metals are indicated with unfilled arrows.221
Figure 2: Zn2+ ions stop CAIR decarboxylation. Reaction mixtures (1.26222
mL final volume) at 30 ◦C contained 50 mM Tris•HCl, pH 8.0, 42 µM CAIR,223
and 0.13 µg Acetobacter aceti PurE1 (0.005 units) [23]. At 5 min, ZnSO4224
(0.1 mM) was added to one reaction. Aliquots (0.2 mL) were removed prior225
to the addition of enzyme (zero time point) and at indicated intervals, and226
immediately added to a 1.7 mL centrifuge tube containing a freshly prepared227
mixture of 20% (w/v) trichloroacetic acid / 1.33 M potassium phosphate,228
pH 1.4, (0.1 mL) and 0.1% (w/v) sodium nitrite (0.1 mL). After 3 min, 0.5%229
(w/v) ammonium sulfamate (0.1 mL) was added to destroy excess nitrite.230
After an additional min, Bratton-Marshall reagent [0.1 mL of 0.1% (w/v)231
N -(1-naphthyl)ethylenediamine dihydrochloride] was added. After 10 min,232
the solution (0.6 mL) was centrifuged (16 000g, 30 s) to eliminate bubbles233
and the absorbance at 500 nm (A500) was recorded.234
CAIR consumption was quantitated using a differential extinction coef-235
ficient for CAIR to AIR conversion, ∆ε500 = ε
AIR-BM
500 − εCAIR-BM500 = 13 600 ±236




500 was from a control reaction in which CAIR was238
completely converted to AIR.239
The symbols and error bars represent the mean and standard deviation,240
respectively, for at least three independent replicates of ZnSO4-quenched241
(filled circles) and -unquenched control (open circles) reactions. Concentra-242
tions determined at t > 5 min were significantly different in quenched and243
control reaction mixtures [one-tailed t-test, P -value < 0.01 (**) or < 0.001244
(***)]. The slope of the line connecting the first two points corresponds to245
0.003 units of enzyme activity, comparable to the 0.004 units expected under246
the reaction conditions [23].247
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